About Tolerx
Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy in Phase 3 development for type 1 diabetes, for which Tolerx is partnered with GlaxoSmithKline. A second clinical product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for cancer. TRX1, a third immunotherapy candidate, is an anti-CD4 antibody that has been clinically evaluated for the treatment of aberrant or untoward immune responses.
The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and are being evaluated for potential benefit in the treatment of cancer and chronic viral infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.
|
|
|
1-10 employees
View all Tolerx employees
|
|
Biotechnology
|
|
300 Technology Square, 3rd Floor, Cambridge, MA 02139, US
|
|
2000
|
|
Biotechnology, Immunotherapy, Cancer Treatment, Antibody Treatment, Autoimmune Disease, Diabetes Treatment
|
Tolerx Alternatives
Frequently Asked Questions about Tolerx
Tracey Dembro is the CEO of Tolerx, Inc..
Tolerx Staff Directory
Search Tolerx Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
